These frequencies were consistent with a retrospective observational study conducted in 2017 (the BRAVE study; 34.7% in EGFR, 6.9% in ALK) regarding the choice of first-line chemotherapy in cases of advanced and metastatic NSCLC [17]. This evidence concerns the gene ALK and non-small cell lung carcinoma.